** Shares of drug developer Ideaya Biosciences IDYA.O fall 4.6% to $20.94
** Co reports Q4 net loss of $130.3 million compared with net loss of $34.0 million a year ago
** Collaboration revenue for the quarter was $7 million compared to $3.9 million a year earlier
** Co received milestone payment from GSK GSK.L
** As of December 31, co had cash, cash equivalents and marketable securities of about $1.1 billion, compared to $632.6 million a year earlier
** Separately, co entered into an additional clinical study collaboration and supply agreement with Gilead Sciences GILD.O to test IDYA's experimental drug, IDE397, in combination with GILD's trodelvy to treat a type of lung cancer
** In the last 12 months, IDYA has fallen ~53%
(Reporting by Siddhi Mahatole)
((siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.